Radiation Therapy for Orbital Mucosa-Associated Lymphoid Tissue Lymphoma: What is the Optimal Radiation Dose?

Masaharu Hata1,2*
1Division of Radiation Oncology, Department of Oncology, Yokohama City University, Graduate School of Medicine, Japan
2Department of Radiology, Yokohama City University Graduate School of Medicine, Japan

Abstract

Primary orbital lymphoma is a rare malignancy that accounts for only 1% of all lymphomas, and more than half of orbital lymphomas present histology of marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT). MALT lymphoma is an indolent and slow growing disease that is very radiosensitive. Radiation therapy is thus the first choice of curative treatment for MALT lymphoma. The total dose of approximately 30 Gy in conventional fractions has been most frequently used for the treatment of MALT lymphoma, and has achieved an excellent local control rate of ≥ 95%. Recently, the total dose has been reduced to 24 Gy to 25 Gy in some institutions. Furthermore, low dose irradiation with 4 Gy in 2 fractions is also given, but the long-term efficacy is still unclear even though the initial response is good. In contrast, higher dose irradiation with >30 Gy is not recommendable, because there is no evidence that such higher doses enhance the efficacy of local control, and because higher doses can cause unacceptable toxicities, such as severe retinopathy.

Keywords: Malignant lymphoma; Mucosa-associated lymphoid tissue lymphoma; Orbit; Orbital lymphoma; Radiation therapy

Introduction

Primary lymphoma in the orbit, mainly ocular adnexa, is a relatively rare malignancy that accounts for only 1% of all lymphomas, and around 10% of extranodal lymphomas [1-3]. In more than half of patients with orbital lymphoma, the histological subtype presents marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) [3,4]. In 1983, Isaacson and Wright first described MALT lymphoma, which was subsequently classified by the World Health Organization [5,6]. MALT lymphoma is characterized by indolent and slow growing disease. Although approximately 30% of all MALT lymphomas are found to be accompanied with distant involvement at diagnosis, generally orbital MALT lymphoma is associated with a low malignant potential and a favorable prognosis in patients [7-9].

Radiation Therapy

Radiation therapy has been applied in the treatment of orbital MALT lymphoma, and is now considered as the standard and most reliable curative treatment. We previously published a report on radiation therapy outcomes for orbital MALT lymphoma [10]. A total of 30 patients with orbital MALT lymphoma received external irradiation with the radiation fields including the gross tumor plus a 1 cm to 2 cm margin using 4 MV to 6 MV X-rays or 7 MeV to 13 MeV electrons. The typical dose distribution in the treatment planning with X-rays is shown in Figure 1. Clinical stages were stage I, A in 29 patients with tumors localized in the orbit, and stage II, A in one with cervical lymph node involvement. Three patients had tumors in the bilateral orbits. The median total dose of 30 Gy in 2 Gy fractions was delivered to the tumors, including the involved cervical lymph node. To protect the eye, a lead or tungsten shield was used for three patients treated with electrons. As a result, all irradiated tumors were completely controlled. All symptoms which patients had before treatment, including diplopia, proptosis, and lagophthalmos, disappeared or were markedly improved after treatment. Both the local control and overall survival rates at 5 years in all patients were 100%. Acute reactions, such as radiation-induced conjunctivitis, keratitis, and dermatitis,
Evidence that a dose escalation to >30 Gy improves the local control to be a tolerable dose for the retina [25,26]. In addition, there is no retinopathy, because it is much lower than 45 Gy, which is estimated moderate dose is considered to be safe, and causes no severe toxicities. In fact, there is a report suggesting that aggressive treatment, including radiation therapy, contributes little to prolonged survival of patients with orbital MALT lymphoma, which has low malignant potential and is slow growing [29]. Although it cannot yet be concluded because a lack of data, watchful waiting may be one of the treatment options for patients with disease not presenting aggressive progression.

Conclusions
Radiation therapy is effective in the treatment of orbital MALT lymphoma, and the total dose of 30 Gy is basically safe. It remains unclear at present whether a dose reduction to <30 Gy is really suitable from the viewpoint of long-term disease control. It is expected that the optimal radiation dose will be determined by further studies in the near future, ideally randomized controlled trials.

References


